| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide Cardiovascular disease, Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Completed | 833 | Jun 2023 | 19 | results |
| ELIXAEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) | Lixisenatide Cardiovascular disease, Type 2 diabetes | - | Ph 3 | Completed | 829 | Feb 2015 | 12 | results |
| HF-POLARISA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Amycretin / zenagamtide Heart failure, Obesity / overweight | - | Ph 3 | Not yet recruiting | 825 | Jul 2029 | - | |
| MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Maridebart cafraglutide / MariTide Cardiovascular disease, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 777 | Jun 2028 | - | |
| NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Retatrutide Cardiovascular disease, Chronic kidney disease, Obesity / overweight | BMI ≥27 · Established ASCVD/CKD | Ph 3 | Active, not recruiting | 745 | Feb 2029 | 1 | |
| SURMOUNT-MMOA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Tirzepatide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 671 | Oct 2027 | 1 | |
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 · Established CVD | Ph 3 | Completed | 635 | Jun 2025 | 4 | |
| REDEFINE 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema / cagrilintide, Semaglutide Cardiovascular disease, Obesity / overweight | HbA1c 6.5-10% | Ph 3 | Active, not recruiting | 631 | Sep 2027 | - | |
| NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 629 | Apr 2017 | 18 | results |
| NCT02465515Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | Albiglutide Cardiovascular disease, Type 2 diabetes | Established CVD | Ph 4 | Completed | 607 | Feb 2018 | 7 | results |
| MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Maridebart cafraglutide / MariTide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 605 | Jun 2028 | - | |
| NCT07241390A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | Orforglipron Cardiovascular disease, Chronic kidney disease | Established ASCVD/CKD | Ph 3 | Recruiting | 568 | Aug 2031 | - | |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | - | Ph 3 | Recruiting | 562 | Aug 2030 | - | |
| ESSENCEResearch Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | - | Ph 3 | Active, not recruiting | 556 | Apr 2029 | 3 | |
| NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | Survodutide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 540 | May 2026 | 1 | |
| NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | - | Ph 3 | Recruiting | 526 | Dec 2031 | - | |
| EVOKE PlusA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide Alzheimer's / cognition | - | Ph 3 | Completed | 495 | Sep 2025 | 4 | |
| SOULA Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide Cardiovascular disease, Chronic kidney disease, Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 492 | Aug 2024 | 6 | results |
| NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 444 | Jun 2029 | - | |
| EVOKEA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Semaglutide Alzheimer's / cognition | - | Ph 3 | Completed | 444 | Sep 2025 | 3 | |
| LEADER®Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Liraglutide Cardiovascular disease, Type 2 diabetes | - | Ph 3 | Completed | 428 | Dec 2015 | 41 | results |
| NCT04469855Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic® | Semaglutide Type 2 diabetes | - | - | Completed | 414 | May 2025 | - | |
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide Chronic kidney disease, Type 2 diabetes | HbA1c ≤10% | Ph 3 | Completed | 413 | Jan 2024 | 13 | results |
| REIMAGINE 2A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 405 | Nov 2025 | - | |
| NCT00838903Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 386 | Jan 2012 | 1 | results |
